These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
239 related items for PubMed ID: 10430331
1. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Arora S, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, Podolsky D. Hepatogastroenterology; 1999; 46(27):1724-9. PubMed ID: 10430331 [Abstract] [Full Text] [Related]
2. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. N Engl J Med; 2000 Jun 01; 342(22):1627-32. PubMed ID: 10833208 [Abstract] [Full Text] [Related]
3. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M. N Engl J Med; 1995 Feb 02; 332(5):292-7. PubMed ID: 7816064 [Abstract] [Full Text] [Related]
4. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Charpignon C, Beau P. Gastroenterol Clin Biol; 2008 Feb 02; 32(2):153-7. PubMed ID: 18343615 [Abstract] [Full Text] [Related]
5. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Gastroenterology; 2007 May 02; 132(5):1672-83. PubMed ID: 17484865 [Abstract] [Full Text] [Related]
6. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. Aliment Pharmacol Ther; 2007 Aug 01; 26(3):421-30. PubMed ID: 17635377 [Abstract] [Full Text] [Related]
13. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A, Budesonide CIR United States Study Group. Am J Gastroenterol; 2002 Jul 01; 97(7):1748-54. PubMed ID: 12135030 [Abstract] [Full Text] [Related]
17. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE. Arthritis Rheum; 2001 Jun 01; 44(6):1351-8. PubMed ID: 11407694 [Abstract] [Full Text] [Related]
19. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R. N Engl J Med; 1994 Jun 30; 330(26):1846-51. PubMed ID: 8196727 [Abstract] [Full Text] [Related]